Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2004-01-23
2011-12-27
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S009200, C424S093200, C424S184100, C424S185100, C424S190100, C424S234100, C435S243000, C435S253100, C435S440000, C536S023100, C536S023700
Reexamination Certificate
active
08084041
ABSTRACT:
Methods of treating a mammal that is deficient in CD4+and/or CD8+lymphocytes are provided. The methods comprise inoculating the mammal with an attenuated mycobacterium in theM. tuberculosiscomplex. In these methods, the mycobacterium comprises two deletions, wherein a virulent mycobacterium in theM. tuberculosiscomplex having either deletion exhibits attenuated virulence. Use of these mycobacteria for the manufacture of a medicament for the treatment of mammals deficient in CD4+and/or CD8+lymphocytes is also provided.
REFERENCES:
patent: 5750384 (1998-05-01), Jacobs, Jr. et al.
patent: 5837732 (1998-11-01), Sacchettini et al.
patent: 5955077 (1999-09-01), Andersen et al.
patent: 5968733 (1999-10-01), Bloom et al.
patent: 5972700 (1999-10-01), Jacobs, Jr.
patent: 6015890 (2000-01-01), Jacobs, Jr. et al.
patent: 6221364 (2001-04-01), Paveka et al.
patent: 6221365 (2001-04-01), Jones
patent: 6268201 (2001-07-01), Alland et al.
patent: 6271034 (2001-08-01), Bardarov et al.
patent: 6290966 (2001-09-01), Cox et al.
patent: 6387694 (2002-05-01), McKinney et al.
patent: 6423545 (2002-07-01), Pavelka, Jr. et al.
patent: 6562348 (2003-05-01), Hondalus et al.
patent: 6566121 (2003-05-01), Jacobs, Jr. et al.
patent: 6733761 (2004-05-01), McKinney et al.
patent: 6752994 (2004-06-01), Jacobs, Jr. et al.
patent: 6821769 (2004-11-01), Alland et al.
patent: 2003/0059441 (2003-03-01), Pavelka et al.
patent: 2004/0001866 (2004-01-01), Jacobs et al.
patent: 2005/0260232 (2005-11-01), Sambandamurthy et al.
patent: WO 03/070164 (2003-08-01), None
patent: WO 2006/076343 (2006-07-01), None
patent: WO 2006/076517 (2006-07-01), None
patent: WO 2006/076519 (2006-07-01), None
Waters.W.R. Failure of aMycobacterium tuberculosisdeltaRD1 deltapanCD double deletion mutant in a neonatal calf aerosolM. bovischallenge model: Comparisons to responses elicited byM. bovisbacille Calmette Guerin. Vaccine, vol. 25, pp. 7832-7840, 2007.
Sambandamurthy, V.K., et al., Vaccine, vol. 24, pp. 6309-6320, 2006.
Andersen, P., “Host Responses and Antigens Involved in Protective Immunity toMycobacterium tuberculosis”; Scand. J. Immunol. 1997, pp. 115-131, vol. 45.
Andersen, P., et al., “Proteins Released fromMycobacterium tuberculosisduring Growth”; Infection and Immunity, Jun. 1991, pp. 1905-1910, vol. 59, No. 6.
Behr, M.A., et al., “Comparative Genomics of BCG Vaccines by Whole-Genome DNA Microarray”; Science, May 28, 1999, pp. 1520-1523, vol. 284.
Camacho, L.R., et al., “Identification of a virulence gene cluster ofMycobacterium tuberculosisby signature-tagged transposon mutagenesis”; Molecular Microbiology, 1999, pp. 257-267, vol. 34.
Chambers, M.A., et al., “Identification of aMycobacterium bovisBCG Auxotrophic Mutant That Protects Guinea Pigs againstM. bovisand Hematogenous Spread ofMycobacterium tuberculosiswithout Sensitization to Tuberculin”; Infection and Immunity, Dec. 2000, pp. 7094-7099, vol. 68, No. 12.
Cole, S.T., et al., “Deciphering the biology ofMycobacterium tuberculosisfrom the complete genome sequence”; Nature, Jun. 11, 1998, pp. 537-544 + table pages, vol. 393.
Cox, J., et al., “Complex lipid determines tissue-specific replication ofMycobacterium tuberculosisin mice”; Nature, Nov. 4, 1999, pp. 79-83, vol. 402.
Dascher C.C. et al., “Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis”; International Immunology, Aug. 2003, pp. 915-925, vol. 15, No. 8.
De Voss, J.J., et al. “The salicylate-derived mycobactin siderophores ofMycobacterium tuberculosisare essential for growth in macrophages”; PNAS, Feb. 1, 2000, pp. 1252-1257, vol. 97, No. 3.
Glickman, M.S., et al., “TheMycobacterium tuberculosiscmaA2 Gene Encodes a Mycolic Acid trans-Cyclopropane Synthetase”; The Journal of Biological Chemistry, Jan. 19, 2001, pp. 2228-2233, vol. 276, No. 3.
Gordon, S.V., et al., “Genomics ofMycobacterium bovis”; Tuberculosis, 2001, pp. 157-163, vol. 81(1/2).
Guleria, I., et al., “Auxotrophic vaccines for tuberculosis”; Nature Medicine, Mar. 1996, pp. 334-337, vol. 2, No. 3.
Harboe M. et al., “Evidence for Occurance of the ESAT-6 Protein inMycobacterium tuberculosisand VirulentMycobacterium bovisand for Its Absence inMycobacterium bovisBCG”; Infection and Immunity, Jan. 1996, pp. 16-22, vol. 64, No. 1.
Hernandez-Pando R. et al., “Pathogenesis of Tuberculosis in Mice Exposed to Low and High Doses of an Environmental Mycobacterial Saprophtye before Infection”; Infection and Immunity, Aug. 1997, pp. 3317-3327, vol. 65, No. 8.
Hondalus, M.K., et al., “Attenuation of and Protection Induced by a Leucine Auxotroph ofMycobacterium tuberculosis”; Infection and Immunity, May 2000, pp. 2888-2898, vol. 68, No. 5.
Hsu, T., et al., “The primary mechanism of attenuation of bacillus Calmette-Guérin is a loss of secreted lytic function required for invasion of lung interstitial tissue”; PNAS, Oct. 2003, pp. 1240-1225, vol. 100, No. 21.
Jackson, M., et al., “Persistence and Protective Efficacy of aMycobacterium tuberculosisAuxotroph Vaccine”; Infection and Immunity, Jun. 1999, pp. 2867-2873, vol. 67, No. 6.
Ladel, C.H., et al., “Immune response toMycobacterium bovisbacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance”; Eur. J. Immunol., 1995, pp. 377-384, vol. 25.
Mahairas, G.G., et al., “Molecular Analysis of Genetic Differences betweenMycobacterium bovisBCG an VirulentM. bovis”; Journal of Bacteriology, Mar. 1996, pp. 1274-1282, vol. 178, No. 5.
Manca, C., et al., “Virulence of aMycobacterium tuberculosisclinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta”; PNAS, May 8, 2001, pp. 5752-5757, vol. 98, No. 10.
McKinney, J.D., et al., “Persistence ofMycobacterium tuberculosisin macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase”; Nature, Aug. 17, 2000, pp. 735-738, vol. 406.
Mogues, T., et al., “The Relative Importance of T Cell Subsets in Immunity and Immunopathology of AirbornMycobacterium tuberculosisInfection in Mice”; J. Exp. Med., Feb. 2001, pp. 271-280, vol. 193, No. 3.
Moreira A.L. et al., “Mycobacterial Antigens Exacerbate Disease Manifestations inMycobacterium tuberculosis-Infected Mice”; Infection and Immunity, Apr. 2002, pp. 2100-2107, vol. 70, No. 4.
Pavelka, Jr., M.S. and Jacobs, Jr., W.R., “Comparison of the Construction of Unmarked Deletion Mutations inMycobacterium smegmatis, Mycobacterium bovis, Bacillus Calmette-Guerin, andMycobacterium tuberculosisH37Rv by Allelic Exchange”, Journal of Bacteriology, Aug. 1999, pp. 4780-4789, vol. 181, No. 16.
Sambandamurthy V.K. et al., “A pantothenate auxotroph ofMycobacterium tuberculosisis highly attenuated and protects mice against tuberculosis”; Nature Medicine, Oct. 2002, pp. 1171-1174, vol. 8, No. 10.
Sambandamurthy V.K. et al., “Long-Term Protection against Tuberculosis following Vaccination with a Severely Attenuated Double Lysine and Pantothenate Auxotroph ofMycobacterium tuberculosis”; Infection and Immunity, Feb. 2005, pp. 1196-1203, vol. 73, No. 2.
Sampson S.L. et al., “Protection Elicited by a Double Leucine and Pantothenate Auxotroph ofMycobacterium tuberculosisin Guinea Pigs”; Infection and Immunity, May 2004, pp. 3031-3037, vol. 72, No. 5.
Skinner M.A. et al., “A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains ofMycobacterium bovisagainst bovine tuberculosis”; Immunology, Apr. 2003, pp. 548-555, vol. 108, No. 4.
Slyshenkov, V.S., et al., “Pantothenic Acid and Its Derivati
Bardarov Stoyan
Bardarov, legal representative Svetoslav
Hsu Tsungda
Jacobs, Jr. William R.
Morris Sheldon
Albert Einstein College of Medicine of Yeshiva University
Amster Rothstein & Ebenstein LLP
Swartz Rodney P.
LandOfFree
Use of mycrobacterial vaccines in CD4 + or CD8 +... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of mycrobacterial vaccines in CD4 + or CD8 +..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of mycrobacterial vaccines in CD4 + or CD8 +... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4295425